G. Remuzzi

Publications1,668
h-index175
Citations159,882
Highly Influential Citations3,821
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • N. Perico
  • 444 Publications • 89,822 Citations
  • A. Benigni
  • 411 Publications • 21,234 Citations
  • P. Ruggenenti
  • 405 Publications • 25,452 Citations
  • C. Murray
  • 741 Publications • 289,621 Citations
  • Publications
  • Influence
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
TLDR
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
View PDF
COVID-19 and Italy: what next?
View on Elsevier
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
TLDR
Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.
View on PubMed
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global…
View on Elsevier
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.
TLDR
Interventions targeting CKD, particularly to reduce urine protein excretion, are efficacious, cost-effective methods of improving cardiovascular and renal outcomes, especially when applied to high-risk groups and Integration of these approaches within NCD programs could minimize the need for renal replacement therapy.
View on PubMed
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
TLDR
Nonfamilial thrombotic throm bocytopenic purpura is due to an inhibitor of von Willebrand factor-cleaving protease, whereas the familial form seems to be caused by a constitutional deficiency of the protease.
View on PubMed
Delayed graft function in kidney transplantation
View on Elsevier
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
TLDR
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
View on PubMed
Atypical hemolytic-uremic syndrome.
TLDR
Current concepts about the pathobiology of atypical hemolytic–uremic syndrome are reviewed and its diagnosis and management are reviewed.
View on PubMed
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological…
View on Elsevier
...
...